Replies to post #94149 on PharmaCyte Biotech Inc (PMCB)

[A2Z]

Excellent post 1234. You are spot on.

I just refuse to be so gullible as many are

[BioInvestor4]

Great post!

[DragonBear]

I would like to know what’s happening with Mellingen cells development.

The FDA has this rule in, the entire cell implant must be removable. It goes back to the current use of stem cells potentially turning cancerous. Then there's the Melligen cells derived from a human liver cancer cell line. Would the FDA allow it to be used? At a minimum the CIABs would have to be encased in an easily extracted implant.

Ascites development,

As in advanced metastasis usually involving the liver, and lymph nodes. Irritation of the body cavity lining. Back on 11-Dec-18 one had the Medpace PR pump admitting the obvious:

Many patients with pancreatic cancer do have metastatic disease, meaning the spread of the cancer elsewhere in the body, not just a locally advanced disease. This therapy won’t offer a benefit to those patients

There is no Ascites treatment development to be made. It was merely something else Kenny previously pumped without understanding what he was saying.

the Asian plan and diabetes clinical trials.

What Asian plan? If involving diabetes, it has probably already turned out the same as the PC mythical CTs that were suppose to occur in Australia back in 2011(?). It never happened.

Releasing a drop of good information today doesn’t exonerate the ceo

Kenny gave Rabe of recycling 2 yr old news.

And it allows his detractors and defamers to gain ground.

Sure can't have that happen.

[tjclark0551]

1234, IR's response to me about CC

Investor Relations <[e-mail]>

May 5 at 6:32 PM
Dear Mr.,
Please accept our apologies for being so tardy in responding to your email. We just discovered it in our junk mail.
Long ago our CEO said we planned to do quarterly conference calls. However, the subject of deferring those in favor of press release updates was addressed by our CEO in a press release dated May 30, 2018. Here is a link to that press release: https://pharmacyte.com/pharmacyte-biotech-ceo-cso-interviewed-ind-planned-clinical-trial-pancreatic-cancer-cro/
Everyone at PharmaCyte is fully engaged trying to bring its therapy for pancreatic cancer to the point of an IND submission to the FDA. We don’t want to provide an update on every new development we sometimes face daily. The market will react accordingly, even though the issue may have been resolved the next day or even before the update is published.
We will continue to conduct business responsibly. When we have material information to report, we will do so as we always have – publish a press release. We should be publishing an update this coming week.
Thank you for your continued support of the Company.
Investor Relations
23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92630
O 917.595.2856 | F 917.595.2851

[Otsy]

Excellent post. True.